BIIB059
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
ALXN2050-NEPH-201
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age)…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
AEVI-007
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All